One To Watch

Sitryx Therapeutics

A clinical-stage biopharmaceutical company pioneering immunometabolism-based therapies to treat chronic autoimmune and inflammatory diseases through oral small molecules that modulate immune cell metabolism and restore immune balance. Sitryx’s science aims to rebalance immune function by targeting metabolic pathways that govern immune cell behavior.

Company Overview

Sitryx develops disease-modifying therapeutics grounded in the emerging field of immunometabolism. The company’s approach focuses on intracellular metabolic pathways as regulators of immune cell function, aiming to correct dysregulated immune responses rather than broadly suppressing them.

Sitryx has progressed its lead candidate toward clinical evaluation and advanced a differentiated pipeline across multiple autoimmune and inflammatory indications. The company also partners with large pharma for select programs.

Headquarters and Global Presence

Sitryx is headquartered in Oxford, United Kingdom.

Its development strategy includes engagement with both European and US clinical and investor communities, reflecting its dual-continent operational touchpoints.

Founding and History

Sitryx was founded in 2018 by a group of world-leading researchers in immunology and metabolism, with backing from specialist biotech investors.

Early institutional support from SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Lilly and GSK helped establish the science platform and pipeline advancement.

Therapy Areas and Focus

Sitryx prioritizes chronic autoimmune and inflammatory diseases where current therapies often fail to deliver durable remission. Its programs are designed to achieve sustained disease control by modulating key metabolic regulators within immune cells.

Technology Platforms and Modalities

Sitryx’s research engine is built on the premise that metabolic pathways within immune cells determine functional identity and dysregulation. By targeting enzymes and signaling mechanisms that control immune cell metabolism, Sitryx seeks to rebalance immune responses and attenuate pathological inflammation.

Key Proprietary Programs

SYX-5219 – oral modulator of pyruvate kinase M2 (PKM2), in clinical development for atopic dermatitis with Phase I and ongoing Phase Ib studies.
SIT-052 – oral GLS1 inhibitor for allergic asthma and related inflammatory conditions, in preclinical development.
SIT-033 – selective SIK2 inhibitor for ulcerative colitis, positioned for differentiated safety and efficacy.

Key Personnel

Iain Kilty, Chief Executive Officer
Neil Weir, President and Board Member
Pierre Legault, Chairman of the Board
Ravi Rao, Chief Medical Officer
Fiona Irvine, Vice President of People and Organization
Ben Stephens, Chief Operating Officer
Adam Mostafa, Chief Financial Officer

Strategic Partnerships

Sitryx has established collaborations to validate its science and de-risk development. Its long-standing exclusive global research and licensing collaboration with Eli Lilly covers autoimmune and inflammatory disease programs.

In February 2026 Sitryx licensed a preclinical oral immunometabolic program to Boehringer Ingelheim in a deal yielding Sitryx upfront and potential milestone payments exceeding $500 million, with tiered royalties on future sales.

FAQ Section

Sitryx targets immune cell metabolism to rebalance dysregulated immune responses in chronic autoimmune and inflammatory diseases. Its goal is to deliver disease-modifying therapies rather than simply suppress symptoms.

The company’s pipeline spans atopic dermatitis, allergic asthma, ulcerative colitis and other immune-mediated conditions where restoring immune balance through metabolic modulation could offer durable benefit.

Key programs include SYX-5219 in clinical development for atopic dermatitis and preclinical small molecule candidates such as SIT-052 and SIT-033 for asthma and ulcerative colitis, respectively.

SYX-5219 is an oral modulator of the metabolic enzyme PKM2, intended to normalize lymphocyte metabolism and drive sustained immune remission in inflammatory disease.

In February 2026 Sitryx licensed a preclinical oral immunometabolic program to Boehringer Ingelheim in a transaction with potential milestones above $500 million, underscoring external validation of its small molecule science.

Rather than broadly suppressing immune responses, Sitryx’s strategy aims to modulate underlying metabolic pathways that govern immune cell activation, with the potential for more precise and durable disease control.

Key value inflection points include Phase Ib and Phase II clinical data for SYX-5219, IND progression for other oral small molecules, and delivery of readouts that demonstrate sustained immune rebalancing in target indications

Want to Update your Company's Profile?